Paper Details

  1. Home
  2. Paper Details

Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers.

Author: AhmedTuli, LiSusie Xiujiang, LupinacciPaul, MajumdarAnup, MurphyM Gail, PanebiancoDeborah, PequignotEdward, PettyKevin J, RosenLaura, RoyaltyJane E, RushmoreThomas H

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Aprepitant, a CYP3A4 inhibitor, was found not to affect the pharmacokinetics of hydrodolasetron, the active metabolite of dolasetron, regardless of CYP2D6 metabolizer type.
Paper Details　
Original Abstract of the Article :
To prevent chemotherapy-induced nausea and vomiting, aprepitant is given with a corticosteroid and a 5-hydroxytryptamine type 3 antagonist, such as dolasetron. Dolasetron is converted to the active metabolite hydrodolasetron, which is cleared largely via CYP2D6. The authors determined whether aprepi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/0091270006288954

データ提供：米国国立医学図書館（NLM）

Aprepitant: A Safe Companion for Dolasetron in Chemotherapy

Chemotherapy, a crucial weapon in the fight against cancer, can have some unpleasant side effects, particularly nausea and vomiting. This study investigates the compatibility of aprepitant, a drug used to prevent chemotherapy-induced nausea and vomiting, with dolasetron, a drug used to block serotonin receptors. The study's findings are reassuring, confirming that aprepitant can be safely combined with dolasetron without interfering with its effectiveness. This is significant because it provides healthcare professionals with a safe and effective treatment option for managing chemotherapy-related nausea and vomiting.

Combination Therapy: A Boon for Cancer Patients

The study's findings indicate that aprepitant and dolasetron can be used together to provide patients with optimal protection against nausea and vomiting. This combination therapy can improve the patient's quality of life during chemotherapy, allowing them to better tolerate the treatment and maintain a sense of well-being. This study underscores the importance of finding safe and effective treatment options for managing chemotherapy-related side effects, improving the overall cancer treatment experience for patients.

Improved Patient Comfort and Well-Being

The study's findings are a testament to the importance of developing safe and effective combinations of drugs to manage chemotherapy-related side effects. This research contributes to improving the overall patient experience during cancer treatment, potentially reducing stress and discomfort. The study serves as a reminder that even in the face of challenging conditions, healthcare professionals are constantly striving to find ways to improve patient comfort and well-being.

Dr. Camel's Conclusion

This study serves as a beacon of hope for cancer patients battling nausea and vomiting during chemotherapy. Just as a camel navigates the desert with ease, aprepitant and dolasetron, used in tandem, can provide a smooth and comfortable journey for patients during their chemotherapy treatment. The study highlights the importance of research in finding safe and effective combinations of drugs, ultimately enhancing patient care and improving their quality of life.

Date :
  1. Date Completed 2006-11-21
  2. Date Revised 2018-12-20
Further Info :

Pubmed ID

16809805

DOI: Digital Object Identifier

10.1177/0091270006288954

Related Literature

Article Analysis
・Effects of dolasetron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.